Streetbeat News

Stock Prices

PRZO

ParaZero Technologies' shares are up following the announcement that they helped a customer secure the first light uncrewed aircraft system operator certificate in Denmark.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 1:55 pm

TC

Trading for TC has been halted and then resumed at 8:55 AM ET, with updated quotation resumption times provided.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 1:55 pm

SCCO

TSLA

UBER

Tesla, Inc. (TSLA) shares fell over 12% after reporting Q4 revenue and EPS that missed consensus estimates. Southern Copper Corporation (SCCO) was downgraded by Morgan Stanley from Equal-Weight to Underweight with a reduced price target. Uber Technologies, Inc. (UBER) reached a new all-time high and is showing interest in federal marijuana lobbying, which could benefit from the SAFE Banking Act.

Portfolio Pulse from Avi Kapoor

January 26, 2024 | 1:53 pm

REGN

SNY

The FDA has approved Regeneron Pharmaceuticals Inc and Sanofi SA's Dupixent for treating eosinophilic esophagitis (EoE) in children aged 1 to 11 years. This expands on the initial approval for patients 12 years and older. The approval is based on a Phase 3 trial showing significant efficacy. Approximately 21,000 U.S. children are treated for EoE with unapproved therapies, indicating a substantial market for Dupixent. REGN shares saw a slight increase of 0.14% in premarket trading, while SNY shares rose by 0.92%.

Portfolio Pulse from Vandana Singh

January 26, 2024 | 1:53 pm

CRBP

Corbus Pharmaceuticals' stock is trading higher following the announcement of positive data from the first-in-human clinical study of CRB-701. The data is being presented by its development partner CSPC Pharmaceutical at the ASCO GU 2024 conference.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 1:52 pm

PAYS

RVP

TGEN

VANI

Insiders at PaySign, Retractable Technologies, Tecogen, and Vivani Medical have recently made notable purchases of their companies' stocks. PaySign's 10% owner acquired shares at $2.79 each, Retractable Technologies' CEO and President bought shares at $1.22 each, Tecogen's Director purchased shares at $0.78 each, and Vivani Medical's Director bought shares at $1.01 each. These transactions can signal insider confidence and may influence investor decisions, especially those interested in penny stocks.

Portfolio Pulse from Avi Kapoor

January 26, 2024 | 1:52 pm

EPIX

ESSA Pharma Inc (NASDAQ:EPIX) shares dropped 22.6% to close at $6.80 after presenting updated data from a Phase 1/2 study of masofaniten in combination with enzalutamide for prostate cancer treatment. The study showed positive results, with significant reductions in PSA levels among patients. Despite the promising data, the stock experienced a significant decline. The company has sufficient cash to fund operations through 2025. EPIX stock is down 1.03% in premarket trading.

Portfolio Pulse from Vandana Singh

January 26, 2024 | 1:51 pm

LEVI

Wells Fargo analyst Ike Boruchow has maintained an Equal-Weight rating on Levi Strauss (NYSE:LEVI) but reduced the price target from $18 to $17.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 1:50 pm

V

Wedbush analyst Moshe Katri has maintained an Outperform rating on Visa (NYSE:V) and increased the price target from $270 to $280.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 1:50 pm

SGMT

Sagimet Biosciences has priced its public offering of 9 million shares at $12.50 per share, leading to a decline in its stock price.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 1:48 pm